Rigel Pharmaceuticals (RIGL) Revenue Growth (5y) (2015 - 2026)
Rigel Pharmaceuticals (RIGL) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 700.30 Mn | 553.62 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.20% |
| Dec 31, 2025 | 30.49% |
| Sep 30, 2025 | 30.45% |
| Jun 30, 2025 | 44.71% |
| Mar 31, 2025 | -0.89% |
| Dec 31, 2024 | 30.19% |
| Sep 30, 2024 | 21.54% |
| Jun 30, 2024 | 28.77% |
| Mar 31, 2024 | 18.53% |
| Dec 31, 2023 | -1.12% |
| Sep 30, 2023 | 42.05% |
| Jun 30, 2023 | 71.98% |
| Dec 31, 2022 | 68.13% |
| Sep 30, 2022 | 90.21% |
| Mar 31, 2022 | 36.10% |
| Dec 31, 2021 | 46.74% |
| Sep 30, 2021 | 41.78% |
| Jun 30, 2021 | 25.04% |
| Mar 31, 2021 | 74.35% |
| Dec 31, 2020 | 16.66% |